In parallel, a randomized non-inferiority trial involving RAS/BRAF status and primary tumor sites to evaluate the addition of anlotinib vs. bevacizumab to XELOX/FOLFOX is also required in the future. This evidence concerns the gene BRAF and neoplasm.